Harvest One’s Dual Strategy Sets It Apart from Other LPs
Ryan Allway
June 2nd, 2017
News, Top News
The global cannabis industry is rapidly gaining steam following medical and recreational legalization in Canada and liberalization of cannabis laws elsewhere around the world. Investors have many different options for investing in the space – including both the medical and recreational side of the business – but few companies offer exposure to both and even fewer offer exposure to the global industry rather than a country-specific focus.
In this article, we’ll look at Harvest One Cannabis Inc.’s (TSX-V: HVST) dual strategy and how it can help investors diversify their exposure to the cannabis industry.
Many Different Approaches
The Canadian cannabis industry is expected to surpass C$22.6 billion over the coming years, according to Deloitte Canada, as recreational use goes into effect next year. Not surprisingly, the rapidly growing industry has attracted billions of dollars in capital and thousands of entrepreneurs. These companies are taking a wide range of approaches, from developing recreational brands to studying medicinal benefits.
Licensed producers are taking the straightest approach to the industry by directly cultivating cannabis under the Access to Cannabis for Medical Purposes Regulations (ACMPR). With only about 40 licensed producers, PI Financial analysts expect that there will be a shortfall in supply until 2020 as they struggle to keep up with rising demand. Some licensed producers have focused on maximizing production while others have tried to build up a niche.
These licensed producers can be generally divided into those focused on medical cannabis and those focused on recreational usage. Medically-focused companies are focused on developing clinically-differentiated product lines designed to target specific medical conditions, while recreationally-focused companies are largely focused on large-scale production and branding efforts in conjunction with famous marijuana celebrities.
There’s also an increasing opportunity for medical marijuana outside of Canada as a growing number of countries liberalize their laws. For example, Prohibition Partners recently issued a report finding that Europe’s cannabis industry could reach 18 billion over the coming years. Relatively few public companies are well-positioned to capitalize on these international markets given the underdeveloped status of the industry compared to Canada or the United States.
Dual Strategy for Diversification
Investors face a tough decision when deciding where to invest in licensed producers. Some of these companies have targeted both segments of the market – such as Canopy Growth Corp. (TSX: WEED) – but their valuations tend to be on the high end of the spectrum. Those targeting only medical cannabis may achieve near-term revenue, but they could be leaving money on the table when it comes to the much larger recreational market.
Harvest One has developed a ‘dual strategy’ designed to target both markets within a single publicly-traded entity. The company accomplishes this through two wholly-owned subsidiaries targeting each market. And unlike many competitors, these companies are targeting more than just Canada – they’re targeting the global cannabis industry.
United Greeneries is a Canadian ACMPR licensed producer that will serve as the company’s horticulture arm and recreational brand. With current capacity for 1,000 kilograms per year, the company plans to immediately expand capacity by 7,500 kilograms per year in 12 months and 50,000 kilograms per year onward, according to its investor presentation. The company’s Lucky Lake property with 12,000 kilograms per year of capacity is also nearing approval.
Satipharm is a cannabis-based health products firm specializing in the development and manufacturing of medical products. In particular, the company secured global exclusive rights to Gelpell® Microgel Capsules for cannabis applications. The company generates near-term revenue from supplement sales in the European Union with mid-term growth from entry into regulated markets in Canada, Australia, and elsewhere around the world.
The company’s Gelpell products contain a controlled delivery system that enhances oral bioavailability. The capsules are manufactured under Good Manufacturing Practices (GMP) in Switzerland with medical cannabis grown under Good Agricultural and Collection Practices (GACP) in highly-controlled environments. The capsules are also tested to be completely THC-free.
Since undergoing a successful Phase I clinical trial for safety and bioavailability, the product has been approved by the health authorities and prescribing physicians in some countries for the treatment of approved medical conditions.
Looking Ahead
Harvest One Cannabis Inc.’s (TSX-V: HVST) dual strategy represents a compelling way for investors to gain exposure to the rapidly growing cannabis industry. With plans to produce upwards of 7,500 kilograms annually by the end of the year, the company is well on its way to generating revenue and profit from dried cannabis sales. At the same time, its Satipharm division is actively commercializing a leading medical cannabis brand.
For more information, visit the company’s website or investor presentation.
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
About Ryan Allway
Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.
Search CannabisFN
Press Coverage
Psychedelics Index
Top Videos
Matt Hawkins is the founder and managing principal of Cresco Capital Partners, LLC (“Cresco”), a private equity firm focused specifically on investing in the legalized cannabis industry. Since its inception in the summer of 2015, Cresco has made 14 investments out of its first fund and is currently raising this fund, Fund II. Prior to the […]
Tom Zuber is Zuber Lawler & Del Duca’s Managing Partner. He has a degree with highest honors in biomedical engineering and has advised some of the most iconic companies in the world on their patent and trademark portfolios. He is at the cutting edge of cannabis patent and trademark law. He holds degrees from Harvard University and Columbia Law […]
MagicMed Industries intends to partner with pharmaceutical and other companies to develop psychedelic-derived medicinal and licit consumer goods products.
Rubicon Holdings, Inc., a Washington State corporation, is a cannabis company focused on the United States adult use and medical marijuana markets.
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer
